Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24428834 | 0.84 | CHRM1 (0.38) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL12794001 | 0.81 | CHRM1 (0.39) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL20028308 | 0.79 | NOS3 (0.45) | NOS3NOS1NOS2CHRM1CHRM2 | |
| SCHEMBL22725674 | 0.79 | LMNA (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL20927591 | 0.79 | LMNA (0.59) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL22509491 | 0.78 | NOS3 (0.44) | NOS3NOS1NOS2CHRM1CHRM2 | |
| SCHEMBL24428829 | 0.77 | CHRM2 (0.33) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL12793998 | 0.77 | LMNA (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL27012448 | 0.77 | CHRM2 (0.33) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL23696509 | 0.75 | CYP2D6 (0.42) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |